← Human Trials & Peer-Reviewed Studies
Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program
Plain-language guide to PMID 40956259 (2025): double-blind randomized controlled trial study of Semaglutide.
Key Facts
- PMID
- 40956259
- Journal
- JACC. Heart failure
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Pandey A et al. (18 authors)
- DOI
- 10.1016/j.jchf.2025.102610
What This Study Did, in Plain Language
What Was Tested
Researchers studied Semaglutide in this randomized controlled trial publication.
Frailty is common in heart failure with preserved ejection fraction (HFpEF).
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
The authors performed a prespecified, pooled, participant-level analysis of the STEP-HFpEF program that included participants with obesity-related HFpEF.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Semaglutide group a baseline to be compared against.
Dual primary endpoints were changes in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) and BW.
Frailty was estimated using a cumulative deficit-derived frailty index comprising 34 variables across multiple domains at baseline and follow-up.
Effects of semaglutide on frailty burden were also assessed.
What Was Measured
PubMed files the paper under topics including Frailty, Heart Failure, Obesity, Stroke Volume, Weight Loss, Glucagon-Like Peptide-1 Receptor Agonists and Glucagon-Like Peptide 1.
Author keywords: heart failure with preserved ejection fraction.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Semaglutide.
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2025 (JACC. Heart failure), a journal based in United States.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.